Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more
Legend Biotech Corp - Asset Resilience Ratio
Legend Biotech Corp (LEGN) has an Asset Resilience Ratio of 41.66% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Legend Biotech Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Legend Biotech Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $713.70 Million | 41.66% |
| Total Liquid Assets | $713.70 Million | 41.66% |
Asset Resilience Insights
- Very High Liquidity: Legend Biotech Corp maintains exceptional liquid asset reserves at 41.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Legend Biotech Corp Industry Peers by Asset Resilience Ratio
Compare Legend Biotech Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Legend Biotech Corp (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Legend Biotech Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 50.05% | $835.93 Million | $1.67 Billion | +48.37pp |
| 2023-12-31 | 1.68% | $31.00 Million | $1.85 Billion | -16.33pp |
| 2022-12-31 | 18.00% | $239.62 Million | $1.33 Billion | +0.72pp |
| 2021-12-31 | 17.28% | $193.46 Million | $1.12 Billion | +10.36pp |
| 2020-12-31 | 6.92% | $50.00 Million | $722.09 Million | -19.34pp |
| 2019-12-31 | 26.26% | $75.56 Million | $287.71 Million | +24.86pp |
| 2018-12-31 | 1.40% | $6.01 Million | $429.05 Million | -- |